Inventor · disambiguated record
Andrew G. Reaume
Also filed as: REAUME ANDREW · REAUME ANDREW G
24 granted patents·13 pending applications·152 citations·filing 1995–2024
95Inventor score
Files withMELIOR PHARMACEUTICALS I INC19CEPHALON INC5MELIOR DISCOVERY INC4MELIOR PHARMACEUTICALS II LLC4REAUME ANDREW2
Top patents by PatentIndex Score
37 records- 0194US8343985B2Methods for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2010·Granted Jan 1, 2013·17 cites·13 claims
- 0294US7776870B2Methods for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2006·Granted Aug 17, 2010·22 cites·18 claims
- 0393US11534442B2Treatment of adipocytesMELIOR PHARMACEUTICALS I INC·Filed 2020·Granted Dec 27, 2022·6 cites·5 claims
- 0492US8835448B2Methods and formulations for modulating lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2012·Granted Sep 16, 2014·11 cites·20 claims
- 0591US9216959B2Methods and formulations for treating cardiovascular diseaseMELIOR PHARMACEUTICALS I INC·Filed 2014·Granted Dec 22, 2015·10 cites·21 claims
- 0690US10251883B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2017·Granted Apr 9, 2019·5 cites·18 claims
- 0789US11033548B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2019·Granted Jun 15, 2021·4 cites·7 claims
- 0886US10786503B2Treatment of adipocytesMELIOR PHARMACEUTICALS I INC·Filed 2018·Granted Sep 29, 2020·6 cites·5 claims
- 0984US2024408090A1Methods Of Treating Dyskinesia And Related DisordersMELIOR PHARMACEUTICALS II LLC·Filed 2024·Application pending·0 cites
- 1082US5814300AGene-targeted non-human mammals deficient in the SOD-1 geneCEPHALON INC·Filed 1995·Granted Sep 29, 1998·48 cites·4 claims
- 1179US12048697B2Methods of treating dyskinesia and related disordersMELIOR PHARMACEUTICALS II LLC·Filed 2022·Granted Jul 30, 2024·0 cites·14 claims
- 1278US12070461B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2021·Granted Aug 27, 2024·0 cites·16 claims
- 1377US12064432B2Treatment of adipocytesMELIOR PHARMACEUTICALS I INC·Filed 2022·Granted Aug 20, 2024·0 cites·4 claims
- 1473US12011445B2Prevention of pancreatic cell degenerationMELIOR PHARMACEUTICALS I INC·Filed 2019·Granted Jun 18, 2024·1 cites·13 claims
- 1573US2024316048A1Prevention of Pancreatic Cell DegenerationMELIOR PHARMACEUTICALS I INC·Filed 2024·Application pending·0 cites
- 1672US11351169B2Methods of treating dyskinesia and related disordersMELIOR PHARMACEUTICALS II LLC·Filed 2018·Granted Jun 7, 2022·0 cites·9 claims
- 1764US9051312B2Methods of treating dyskinesia and related disordersMELIOR DISCOVERY INC·Filed 2014·Granted Jun 9, 2015·0 cites·14 claims
- 1863US9408844B2Methods for treating inflammatory conditionsMELIOR DISCOVERY INC·Filed 2014·Granted Aug 9, 2016·0 cites·23 claims
- 1962US9763945B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2015·Granted Sep 19, 2017·0 cites·8 claims
- 2061US8716294B2Methods for treating inflammatory conditionsREAUME ANDREW·Filed 2007·Granted May 6, 2014·0 cites·25 claims
- 2158US6734336B1Gene-targeted non-human mammal with human fad presenilin mutation and generational offspringCEPHALON INC·Filed 2000·Granted May 11, 2004·3 cites·40 claims
- 2256US10188651B2Methods of treating sleep disordersMELIOR PHARMACEUTICALS II LLC·Filed 2016·Granted Jan 29, 2019·0 cites·10 claims
- 2356US9402830B2Methods of treating dyskinesia and related disordersMELIOR DISCOVERY INC·Filed 2015·Granted Aug 2, 2016·0 cites·12 claims
- 2454US2020215068A1Treatment of type i and type ii diabetesMELIOR PHARMACEUTICALS I INC·Filed 2020·Application pending·0 cites
- 2553US2017173004A1Methods For Treating Inflammatory ConditionsMELIOR DISCOVERY INC·Filed 2016·Application pending·0 cites
- 2652US5777194AGene-targeted mice with humanized Aβ sequence and Swedish FAD mutationCEPHALON INC·Filed 1996·Granted Jul 7, 1998·16 cites·5 claims
- 2751US2021106581A1Treatment Of Liver DiseasesMELIOR PHARMACEUTICALS I INC·Filed 2019·Application pending·0 cites
- 2850US2004154047A1Gene-targeted non-human mammal with human FAD presenilin mutation and generational offspringCEPHALON INC·Filed 2004·Application pending·0 cites
- 2949US2022031700A1Treatment of Acute Respiratory Distress Syndrome (ARDS)MELIOR PHARMACEUTICALS I INC·Filed 2021·Application pending·0 cites
- 3048US2010152215A1Methods of identifying activators of lyn kinaseMELIOR PHARMACEUTICALS I INC·Filed 2008·Application pending·0 cites
- 3147US2013158055A1Prevention Of Pancreatic Beta Cell DegenerationREAUME ANDREW G·Filed 2011·Application pending·0 cites
- 3245US2010197710A1Methods Of Activating IRS-1 And AKTMELIOR PHARMACEUTICALS I INC·Filed 2008·Application pending·0 cites
- 3345US2015190396A1Treatment of type i and type ii diabetesMELIOR PHARMACEUTICALS I INC·Filed 2012·Application pending·0 cites
- 3440US8552184B2Compounds and methods for treating disorders related to glucose metabolismREAUME ANDREW G·Filed 2009·Granted Oct 8, 2013·0 cites·20 claims
- 3538US2007105878A1Purine formulations and methods for managing disordersREAUME ANDREW·Filed 2006·Application pending·0 cites
- 3633US2003092183A1Rapid creation of gene targeting vectors using homologous recombination in yeastFiled 2001·Application pending·0 cites
- 3732US6284944B1Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspringCEPHALON INC·Filed 1998·Granted Sep 4, 2001·3 cites·10 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →